U.S. markets closed
  • S&P Futures

    +9.00 (+0.23%)
  • Dow Futures

    +58.00 (+0.19%)
  • Nasdaq Futures

    +42.50 (+0.36%)
  • Russell 2000 Futures

    +3.10 (+0.18%)
  • Crude Oil

    +2.08 (+2.09%)
  • Gold

    +5.10 (+0.29%)
  • Silver

    +0.08 (+0.44%)

    -0.0001 (-0.01%)
  • 10-Yr Bond

    -0.0800 (-2.77%)
  • Vix

    +0.01 (+0.04%)

    +0.0015 (+0.12%)

    -0.1830 (-0.13%)

    -112.49 (-0.55%)
  • CMC Crypto 200

    -0.83 (-0.19%)
  • FTSE 100

    -207.18 (-2.86%)
  • Nikkei 225

    -263.22 (-1.00%)

Global Meningitis Vaccines Market to Surpass US$ 6,669.3 Million by 2030 - Coherent Market Insights

·5 min read

SEATTLE, June 20, 2022 /PRNewswire/ -- According to Coherent Market Insights, the global meningitis vaccines market is estimated to be valued at US$ 4,070.1 million in 2022 and is expected to exhibit a CAGR of 6.4% during the forecast period (2022-2030).

Coherent Market Insights Logo
Coherent Market Insights Logo

Key Trends and Analysis of the Global Meningitis Vaccines Market:

Key companies are focusing on obtaining product licenses from regulatory authorities in order to provide high quality meningitis vaccines around the globe, which is expected to boost market growth over the forecast period. For instance, in December 2020, the China National Medical Products Administration approved and issued a product license for the 23-valent pneumococcal polysaccharide vaccine of Sinovac Biotech Ltd., a China-based biopharmaceutical company. This vaccine is indicated for the prevention of blood infection (bacteremia), pneumonia, and meningitis (infection of the covering of the brain) due to the bacteria – Streptococcus pneumonia.

Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/5042

Key Market Takeaways:

Global meningitis vaccines market is expected to exhibit a CAGR of 6.4% during the forecast period, owing to the increasing research and development activities in developing meningitis vaccines by key players in market. For instance, in June 2021, the Serum Institute Of India Pvt. Ltd., one of the world's largest vaccine manufacturers, announced the results from a Phase 2 clinical study of a pentavalent meningococcal meningitis vaccines designed for utilization in the African meningitis, to be well-tolerated, safe, and capable of generating powerful immune reaction to all five serogroups A, B, C, W, and X

Among vaccines, the pneumococcal conjugate vaccine segment is expected to dominate the segment growth over the forecast period, owing to increased product approvals from the regulatory bodies. For instance, in June 2021, Pfizer Inc., a multinational pharmaceutical and Biotechnology Corporation, announced that the U.S. Food and Drug Administration (FDA) had approved PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) for the prevention of invasive diseases such as meningitis and pneumonia caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes, in adults aged 18 years and older

On the basis of age group, the infant segment is expected to dominate the segment growth over the forecast period, owing to increasing research studies by key players on meningitis vaccines. For instance, in March 2022, researchers at the  University of Maryland School of Medicine (UMSOM)'s Center for Vaccine Development & Global Health (CVD) carried out a study to evaluate the use of a pentavalent or five in one meningococcal conjugate vaccine (NmCV-5) among infants and young children in the meningitis belt of sub-Saharan Africa. This is the final and pivotal study for World Health Organization (WHO) prequalification of the vaccine, which is the last stage to make the vaccine available for low- and middle-income countries

Key players operating in the global meningitis vaccines market include GlaxoSmithKline plc., Sanofi S.A., Merck & Co., Inc., Pfizer Inc., Novartis AG, Walvax Biotechnology Co., Ltd., Incepta Pharmaceuticals Ltd., Serum Institute of India Pvt. Ltd., Vacsera, Zhi Fei Biological, BIO MED, Chengdu Kanghua Biological Products, Bharat Biotech., LG Chem, Espromed Bio, Panacea Biotec Limited, Sinovac Biotech Co., Ltd., CanSinoBIO, and Eubiologics Co., Ltd.

Request for Customization @ https://www.coherentmarketinsights.com/insight/request-customization/5042

Detailed Segmentation:

Global Meningitis Vaccines Market, By Vaccine:

  • Pneumococcal Conjugate Vaccine

  • Pneumococcal Polysaccharide Vaccine

  • Meningococcal Vaccine

  • Others

Global Meningitis Vaccines Market, By Age Group:

  • Infants

  • Adults

Global Meningitis Vaccines Market, By Distribution Channel:

  • Government

  • Private

Global Meningitis Vaccines Market, By Country:

  • Egypt

  • Nigeria

  • Morocco

  • Indonesia

  • Bangladesh

  • Malaysia

  • United Arab Emirates

  • Saudi Arabia

  • Pakistan

  • Turkey

  • Kazakhstan

  • Jordan

  • Qatar

  • Sudan

  • Lebanon

  • Uganda

  • Benin

  • Cameroon

  • Gabon

  • Cote d'Ivoire

  • Vietnam

  • Singapore

  • Mexico

  • Argentina

  • Thailand

  • Philippines

  • Nepal

  • Rest of the World

Buy this Complete Report Now @ https://www.coherentmarketinsights.com/insight/buy-now/5042

Find more related trending reports below:

Meningitis Diagnostic Testing Market, by Infection Type (Bacterial, Viral, and Fungal), by Diagnosis Type (Latex Agglutination Tests, Lateral Flow Assay Tests, PCR Assay Tests, ELISA Tests, and Culture Test), by End User (Hospitals, Diagnostic Laboratories, Ambulatory Surgical Centers, and Others), and by Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022-2028

Meningitis Treatment Market, By Causative Micro-organism (Bacterial, Viral, and Fungal), By Treatment Type (Antibiotic Therapy and Adjunctive Therapy), By Vaccine Type (Meningococcal Conjugate Vaccine, Meningococcal Polysaccharide Vaccine (MPSV4), and Combination Vaccine) - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022-2028

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

Contact Us:

Mr. Shah
Senior Client Partner – Business Development
Coherent Market Insights
US: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +81-050-5539-1737
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com 
Website: https://www.coherentmarketinsights.com
Follow Us: LinkedInTwitter

Logo: https://mma.prnewswire.com/media/902389/Coherent_Market_Insights_Logo.jpg


View original content:https://www.prnewswire.com/news-releases/global-meningitis-vaccines-market-to-surpass-us-6-669-3-million-by-2030--coherent-market-insights-301571212.html

SOURCE Coherent Market Insights